Song A, Wang Q, Goebl M G, Harrington M A
Department of Biochemistry and Molecular Biology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
Mol Cell Biol. 1998 Sep;18(9):4994-9. doi: 10.1128/MCB.18.9.4994.
MyoD is a basic helix-loop-helix transcription factor involved in the activation of genes encoding skeletal muscle-specific proteins. Independent of its ability to transactivate muscle-specific genes, MyoD can also act as a cell cycle inhibitor. MyoD activity is regulated by transcriptional and posttranscriptional mechanisms. While MyoD can be found phosphorylated, the functional significance of this posttranslation modification has not been established. MyoD contains several consensus cyclin-dependent kinase (CDK) phosphorylation sites. In these studies, we examined whether a link could be established between MyoD activity and phosphorylation at putative CDK sites. Site-directed mutagenesis of potential CDK phosphorylation sites in MyoD revealed that S200 is required for MyoD hyperphosphorylation as well as the normally short half-life of the MyoD protein. Additionally, we determined that turnover of the MyoD protein requires the proteasome and Cdc34 ubiquitin-conjugating enzyme activity. Results of these studies demonstrate that hyperphosphorylated MyoD is targeted for rapid degradation by the ubiquitin pathway. The targeted degradation of MyoD following CDK phosphorylation identifies a mechanism through which MyoD activity can be regulated coordinately with the cell cycle machinery (CDK2 and CDK4) and/or coordinately with the cellular transcriptional machinery (CDK7, CDK8, and CDK9).
肌分化抗原(MyoD)是一种碱性螺旋-环-螺旋转录因子,参与激活编码骨骼肌特异性蛋白的基因。独立于其反式激活肌肉特异性基因的能力之外,MyoD还可作为一种细胞周期抑制剂。MyoD的活性受转录和转录后机制调控。虽然可以发现MyoD存在磷酸化现象,但这种翻译后修饰的功能意义尚未明确。MyoD含有多个共有细胞周期蛋白依赖性激酶(CDK)磷酸化位点。在这些研究中,我们检测了是否能够在MyoD活性与假定的CDK位点磷酸化之间建立联系。对MyoD中潜在的CDK磷酸化位点进行定点诱变显示,S200是MyoD过度磷酸化以及MyoD蛋白正常较短半衰期所必需的。此外,我们确定MyoD蛋白的周转需要蛋白酶体和Cdc34泛素缀合酶活性。这些研究结果表明,过度磷酸化的MyoD通过泛素途径被靶向快速降解。CDK磷酸化后MyoD的靶向降解确定了一种机制,通过该机制MyoD活性可与细胞周期机制(CDK2和CDK4)和/或与细胞转录机制(CDK7、CDK8和CDK9)协调调控。